Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer
Anisha Jain, Chandan Dharmashekar, Bhargav Shreevatsa K S, Kavitha Raj, Amogha Shivakumar, Shiva Prasad Kollur, Chandan Shivamallu, Ashwini Prasad, M. N. Nagendra Prasad · 2026
Read Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer by Anisha Jain, Chandan Dharmashekar, Bhargav Shreevatsa K S, Kavitha Raj, Amogha Shivakumar, Shiva Prasad Kollur, Chandan Shivamallu, Ashwini Prasad, M. N. Nagendra Prasad (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473559.txt.
Description
A peer-reviewed research article from Europe PMC (2026). KRAS mutations, particularly KRAS G12C, pose significant therapeutic challenges in non-small cell lung cancer (NSCLC) due to limited inhibitor efficacy and rapid resistance. Drug repurposing offers a time and cost-effective strategy to identify alternative therapeutic options targeting KRAS-driven signalling. A structure-based drug repurposing approach was employed to screen FDA-approved compounds targeting key regulators to the MAPK signalling pathway and computationally modelled for potential engagement with the KRAS G12C switch-II pocket.
Catalog record
| CREATOR | Anisha Jain, Chandan Dharmashekar, Bhargav Shreevatsa K S, Kavitha Raj, Amogha Shivakumar, Shiva Prasad Kollur, Chandan Shivamallu, Ashwini Prasad, M. N. Nagendra Prasad |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |